WASHINGTON — The four biggest bosses in artificial intelligence dropped their dukes this week and signed onto a joint letter, telling Congress to slap mandatory screening on every commercial synthetic-DNA outfit in America before a bad actor uses a chatbot to cook up a plague.
Sam Altman of OpenAI. Dario Amodei of Anthropic. Sundar Pichai of Google. Satya Nadella of Microsoft. Four men who fight bare-knuckle every day of the week for the same engineers, the same chips, the same customers — now signing with one pen.
The ask is narrow. The CEOs want federal law forcing every commercial gene-printing house to run customer orders against a database of known dangerous pathogens before the synthesizer hums. No screen, no synthesis.
The fear behind the ink: frontier models are getting capable enough at molecular biology to walk a determined amateur through the wet-lab steps of building something nasty. Anthropic has flagged its own systems for "uplift" risk in this exact domain. OpenAI has matched that warning in its model cards.
A separate letter signed by OpenAI and Anthropic researchers takes aim at AI-developed biological weapons more broadly, published this week through industry safety channels and treated as the opening salvo of a coordinated push on the Hill.
Voluntary screening already exists. The International Gene Synthesis Consortium covers an estimated 80% of the global market. The other slice — small shops, foreign vendors, gray-market players who take a wire transfer and ask no questions — is the gap the CEOs want closed.
Why band together now? Model capabilities keep climbing, and the next generation will make today's safeguards look quaint. Every name on that letter also knows Washington is sharpening its knives, and a unified industry position beats a dozen subpoenas.
Congress has heard the tune before. The 2023 White House executive order on AI asked agencies to draft DNA screening guidance. Most of it never made it into binding statute.
This time the CEOs want binding. Written into law. With teeth. Before the next wave of models hits the public.
The sight is unusual. Amodei left OpenAI to build a competitor. Microsoft pours billions into both Anthropic and OpenAI while running its own Copilot stack. The fact all four signed says the bioweapon risk has moved from talking point to boardroom agenda.
Skeptics will call it a moat. Mandatory screening costs money. Big labs absorb it, small fry cannot, and the men writing the rules happen to run the big labs.
The letter is on the desk. Congress is next.